Corporate | 7 August 2015 07:00
|
Carl Zeiss Meditec AG / Key word(s): 9-month figures
JENA, 7 August 2015
“Boosted by the exchange rates for key currencies, we further increased our revenue after nine months of 2014/15. Our growth comes from all business areas and regions,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. Key figures by business unit at a glance The strongest growth rate was once again achieved by the strategic business unit (SBU) Surgical Ophthalmology, which increased its revenue by 17.3 percent (adjusted for currency effects, 14.2 percent), to EUR 258.5 million (previous year: EUR 220.3 million). Revenue of the Ophthalmic Systems SBU increased by 13.9 percent (adjusted for currency effects, 5.7 percent), to EUR 283.5 million (previous year: EUR 248.9 million). The Microsurgery SBU generated the least growth, increasing its revenue only slightly, to EUR 206.7 million (previous year: EUR 204.5 million). On an adjusted basis, the surgical microscopes and visualization solutions business would have recorded a decline of 4.1 percent. Revenue in Japan, in particular, which is of special significance for this business unit, declined compared with a strong figure the previous year.
Revenue by region The distribution of revenue across the regions in the first nine months of the financial year reflects the general growth trend and the fluctuation of currencies: In the EMEA region (Europe, Middle East and Africa), revenue increased by 8.5 percent, to EUR 261.9 million. Significant growth was achieved in Germany and the United Kingdom, in particular. In the Americas region, the recovery of the U.S. market and the strength of the U.S. dollar led to an 18.8 percent jump in revenue; adjusted for currency effects, however, this growth would have amounted to just 3.7 percent. In the APAC (Asia/Pacific) region, which reported an increase in revenue of 6.4 percent, to EUR 231.6 million, high growth rates from China and India were offset by a declining trend in the Japanese market. Based on the very solid development overall and a product range with strong unique selling points, the Company is aiming to secure its competitive strength in the long term through process and cost optimization measures and targeted investments in new areas of growth. The projections for the financial year remain the same: “We are looking ahead with cautious optimism and are aiming for an EBIT margin – adjusted for strategic upfront R&D investments – of between 13 and 15 percent. Our projected revenue target for the current financial year is still set at a corridor of EUR 960 million to EUR 1,000 million,” says Ludwin Monz. Revenue by strategic business unit
Revenue by region
Press contact:
Investors contact:
2015-08-07 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Carl Zeiss Meditec AG | |
| Göschwitzer Str. 51-52 | ||
| 07745 Jena | ||
| Germany | ||
| Phone: | +49 (0)3641 220-0 | |
| Fax: | +49 (0)3641 220-112 | |
| E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com | |
| Internet: | www.meditec.zeiss.de | |
| ISIN: | DE0005313704 | |
| WKN: | 531370 | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 384599 2015-08-07 |